Ceftibuten

Drug Profile

Ceftibuten

Alternative Names: 7432-S; Cedax; Cepifran; Isocef; SCH 39720; Seftem

Latest Information Update: 11 Nov 2017

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Shionogi
  • Developer Pernix Therapeutics Holdings
  • Class Antibacterials; Cephalosporins; Small molecules
  • Mechanism of Action Cell wall inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Bacterial infections; Otorhinolaryngological infections; Respiratory tract infections

Most Recent Events

  • 25 Mar 2010 Pernix Therapeutics Holdings acquires ceftibuten from Shionogi
  • 31 Aug 2004 Biovail has terminated its sub-licensing and manufacturing agreements for ceftibuten in USA
  • 31 Aug 2004 Ceftibuten has been licensed to Shionogi in USA and Puerto Rico
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top